Page last updated: 2024-10-24

negative regulation of inclusion body assembly

Definition

Target type: biologicalprocess

Any process that decreases the rate, frequency, or extent of inclusion body assembly. Inclusion body assembly is the aggregation, arrangement and bonding together of a set of components to form an inclusion body. [GOC:BHF, GOC:dph, GOC:tb]

Negative regulation of inclusion body assembly is a critical process in protein production, particularly in prokaryotic systems like bacteria. Inclusion bodies are aggregates of misfolded proteins that can form within cells, often during the overexpression of recombinant proteins. These aggregates are typically inactive and can hinder the production of functional proteins.

To prevent the formation of inclusion bodies and promote the production of correctly folded and functional proteins, various mechanisms of negative regulation are employed by cells. These mechanisms can be broadly categorized into two main approaches:

1. **Optimization of Protein Folding:** This involves manipulating the cellular environment to enhance the folding of proteins into their native, functional conformations. This can be achieved through various strategies:

* **Chaperone Expression:** Increasing the expression of chaperone proteins, such as GroEL/ES and DnaK/DnaJ, can assist in proper protein folding and prevent misfolding.
* **Reducing Expression Levels:** Lowering the expression levels of the recombinant protein can reduce the burden on the cellular machinery, allowing for more efficient folding and preventing aggregation.
* **Optimizing Growth Conditions:** Factors like temperature, pH, and nutrient availability can influence protein folding. Optimizing these conditions can enhance protein folding and reduce inclusion body formation.

2. **Preventing Aggregation:** This approach focuses on preventing the initial aggregation of misfolded proteins. Strategies include:

* **Fusion Tags:** Attaching soluble fusion tags to the recombinant protein can improve its solubility and reduce aggregation.
* **Co-expression of Folding Partners:** Co-expressing proteins that interact with the target protein can enhance folding and prevent aggregation.
* **Modification of Protein Sequence:** Modifying the amino acid sequence of the protein, such as introducing mutations that enhance solubility or reduce aggregation propensity, can be effective.

Overall, negative regulation of inclusion body assembly is a complex process that requires a multi-faceted approach. By optimizing protein folding, preventing aggregation, and controlling the cellular environment, the production of correctly folded and functional proteins can be maximized.
'"

Proteins (3)

ProteinDefinitionTaxonomy
Heat shock factor protein 1A heat shock factor protein 1 that is encoded in the genome of human. [PRO:DNx, UniProtKB:Q00613]Homo sapiens (human)
Heat shock-related 70 kDa protein 2A heat shock-related 70 kDa protein 2 that is encoded in the genome of human. [PRO:DAN]Homo sapiens (human)
Heat shock 70 kDa protein 1A A heat shock 70 kDa protein 1A that is encoded in the genome of human. [PRO:DAN, UniProtKB:P0DMV8]Homo sapiens (human)

Compounds (16)

CompoundDefinitionClassesRoles
zm 336372N-(5-(3-dimethylaminobenzamido)-2-methylphenyl)-4-hydroxybenzamide: an inhibitor of c-Raf; activates Raf-1; structure in first sourcebenzamides
adenosine diphosphateAdenosine Diphosphate: Adenosine 5'-(trihydrogen diphosphate). An adenine nucleotide containing two phosphate groups esterified to the sugar moiety at the 5'-position.adenosine 5'-phosphate;
purine ribonucleoside 5'-diphosphate
fundamental metabolite;
human metabolite
adenosinequinquefolan B: isolated from roots of Panax quinquefolium L.; RN not in Chemline 10/87; RN from Toxlitadenosines;
purines D-ribonucleoside
analgesic;
anti-arrhythmia drug;
fundamental metabolite;
human metabolite;
vasodilator agent
8-aminoadenosine
celastrolmonocarboxylic acid;
pentacyclic triterpenoid
anti-inflammatory drug;
antineoplastic agent;
antioxidant;
EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor;
Hsp90 inhibitor;
metabolite
5'-(sulfonylbenzoyl)adenosine5'-(sulfonylbenzoyl)adenosine: covalently binds to platelet membrane
quercetin7-hydroxyflavonol;
pentahydroxyflavone
antibacterial agent;
antineoplastic agent;
antioxidant;
Aurora kinase inhibitor;
chelator;
EC 1.10.99.2 [ribosyldihydronicotinamide dehydrogenase (quinone)] inhibitor;
geroprotector;
phytoestrogen;
plant metabolite;
protein kinase inhibitor;
radical scavenger
chir-265aromatic ether
az-628AZ-628: a multikinase inhibitor; structure in first sourcebenzamides
GDC-0879indanes;
ketoxime;
primary alcohol;
pyrazoles;
pyridines
antineoplastic agent;
B-Raf inhibitor
ver 155008VER 155008: structure in first sourcepurine nucleoside
plx4032aromatic ketone;
difluorobenzene;
monochlorobenzenes;
pyrrolopyridine;
sulfonamide
antineoplastic agent;
B-Raf inhibitor
dabrafenib1,3-thiazoles;
aminopyrimidine;
organofluorine compound;
sulfonamide
anticoronaviral agent;
antineoplastic agent;
B-Raf inhibitor
tak-632TAK-632 : A member of the class of benzothiazoles that is 1,3-benzothiazole substituted by (cyclopropanecarbonyl)amino, 4-fluoro-3-{2-[3-(trifluoromethyl)phenyl]acetamido}phenoxy, and cyano groups at positions 2, 6 and 7, respectively. It is a potent pan-RAF inhibitor with IC50 of 1.4, 2.4 and 8.3 nM for CRAF, BRAF(V600E), BRAF(WT), respectively.(trifluoromethyl)benzenes;
aromatic ether;
benzothiazoles;
cyclopropylcarboxamide;
monofluorobenzenes;
nitrile;
secondary carboxamide
antineoplastic agent;
apoptosis inducer;
B-Raf inhibitor;
EC 2.7.11.26 (tau-protein kinase) inhibitor;
necroptosis inhibitor
dinaciclibpyrazolopyrimidine
n2-(1h-indazole-5-yl)-n6-methyl-3-nitropyridine-2,6-diamineKRIBB11 : A member of the class of indazoles that is 1H-indazole substituted by a [6-(methylamino)-3-nitropyridin-2-yl]amino group at position 5. It is an inhibitor of heat shock factor 1 (IC50 = 1.2muM) and suppresses tumour growth in mouse xenograft models.

N2-(1H-indazole-5-yl)-N6-methyl-3-nitropyridine-2,6-diamine: a heat shock factor 1 antagonist; structure in first source